Renal pathological changes after successful treatment of LCDD using cyclophosphamide, thalidomide, and dexamethasone

Ren Fail. 2021 Dec;43(1):1425-1427. doi: 10.1080/0886022X.2021.1988967.

Authors

Di Wang¹, Yan Wang¹, Shiren Sun¹

Affiliation

¹ Department of Nephrology, Xijing Hospital, the First Affiliated Hospital of Fourth Military Medical University, Xi'an, China.

No abstract available

Publication types

Case Reports
Letter
Video-Audio Media

MeSH terms

Biopsy
Cyclophosphamide / therapeutic use*
Dexamethasone / therapeutic use*
Drug Therapy, Combination
Female
Glucocorticoids / therapeutic use
Humans
Immunoglobulin Light Chains*
Immunosuppressive Agents / therapeutic use
Kidney Diseases / drug therapy*
Middle Aged
Paraproteinemias / drug therapy*
Thalidomide / therapeutic use*

Substances

Glucocorticoids
Immunoglobulin Light Chains
Immunosuppressive Agents
Thalidomide
Dexamethasone
Cyclophosphamide

Grants and funding

This work was supported by grants from the National Natural Science Foundation of China [81600562 and 81700676].